Last reviewed · How we verify
Evrenzo (ROXADUSTAT)
Evrenzo (ROXADUSTAT) is a small molecule developed by Astellas Pharma Europe B.V. that targets the thyroid hormone receptor beta. It is used to treat anemia in chronic kidney disease and refractory anemia. The commercial status of Evrenzo is patented, and its safety considerations include potential effects on blood pressure and heart rate. Evrenzo works by mimicking the action of oxygen on the body, which helps to reduce the production of erythropoietin and subsequently decrease red blood cell production. Further clinical trials are needed to confirm its efficacy and safety.
At a glance
| Generic name | ROXADUSTAT |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Target | Thyroid hormone receptor beta |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2021 |
| Annual revenue | 600 |
Approved indications
- Anemia in chronic kidney disease
- Refractory anemia (clinical)
Common side effects
Key clinical trials
- A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease (PHASE3)
- Study of Roxadustat's Effect on Anemia in Patients With Diabetic Kidney Disease (PHASE4)
- A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) (NA)
- Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting (PHASE2)
- Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
- Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis (PHASE4)
- Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (PHASE4)
- Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evrenzo CI brief — competitive landscape report
- Evrenzo updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI